Spark Therapeutics (NASDAQ:ONCE) was downgraded by Goldman Sachs Group from a “buy” rating to a “neutral” rating in a research note issued to investors on Thursday, Marketbeat reports. They presently have a $58.00 target price on the biotechnology company’s stock, down from their prior target price of $106.00. Goldman Sachs Group’s target price points to a potential upside of 28.29% from the stock’s previous close. The analysts noted that the move was a valuation call.

Several other research analysts have also issued reports on ONCE. UBS lowered shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $92.00 to $51.00 in a research note on Tuesday. BMO Capital Markets set a $73.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. SunTrust Banks set a $101.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 16th. Chardan Capital cut their target price on shares of Spark Therapeutics from $100.00 to $60.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Sanford C. Bernstein set a $71.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $76.19.

Spark Therapeutics (NASDAQ:ONCE) traded down $0.70 on Thursday, hitting $45.21. 1,516,746 shares of the stock traded hands, compared to its average volume of 485,468. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same quarter last year, the company earned ($1.07) earnings per share. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. research analysts anticipate that Spark Therapeutics will post -7.6 EPS for the current year.

In other Spark Therapeutics news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the firm’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total value of $84,630,000.00. Following the transaction, the director now directly owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel Faga sold 1,500 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the transaction, the insider now directly owns 1,500 shares in the company, valued at $127,500. The disclosure for this sale can be found here. Insiders sold 1,068,809 shares of company stock worth $89,809,385 over the last ninety days. Insiders own 7.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the business. Cornerstone Capital Management Holdings LLC. lifted its stake in shares of Spark Therapeutics by 3.2% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock valued at $662,000 after buying an additional 342 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 389 shares in the last quarter. Teachers Advisors LLC lifted its stake in shares of Spark Therapeutics by 1.9% in the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after buying an additional 650 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of Spark Therapeutics by 2.1% in the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock valued at $2,336,000 after buying an additional 800 shares in the last quarter. Finally, Great West Life Assurance Co. Can lifted its stake in shares of Spark Therapeutics by 47.3% in the third quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock valued at $351,000 after buying an additional 1,264 shares in the last quarter. 94.94% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/14/goldman-sachs-group-downgrades-spark-therapeutics-once-to-neutral.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.